Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
August 2, 2021
A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
Edward Kerwin, Paul Dorinsky, Mehul Patel, et al.
Therapeutic Advances in Respiratory Disease
|
August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Klaus F Rabe, Fernando J Martinez, Dave Singh, et al.
Respiratory Medicine
|
March 11, 2008
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Steven M Koenig, John J Murray, James Wolfe, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
Respiratory Medicine
|
June 3, 2018
Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial
Edward Kerwin, Andrew Wachtel, Lawrence Sher, et al.
The European Respiratory Journal
|
September 18, 2018
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
Gary T Ferguson, Alberto Papi, Antonio Anzueto, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Mona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease
|
July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factors
Dave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research
|
July 2, 2021
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
Maarten van den Berge, Jan De Backer, Cedric Van Holsbeke, et al.
Respiratory Medicine
|
June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
August 2, 2021
A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
Edward Kerwin, Paul Dorinsky, Mehul Patel, et al.
Therapeutic Advances in Respiratory Disease
|
August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Klaus F Rabe, Fernando J Martinez, Dave Singh, et al.
Respiratory Medicine
|
March 11, 2008
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Steven M Koenig, John J Murray, James Wolfe, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
Respiratory Medicine
|
June 3, 2018
Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial
Edward Kerwin, Andrew Wachtel, Lawrence Sher, et al.
The European Respiratory Journal
|
September 18, 2018
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
Gary T Ferguson, Alberto Papi, Antonio Anzueto, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Mona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease
|
July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factors
Dave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Research
|
July 2, 2021
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
Maarten van den Berge, Jan De Backer, Cedric Van Holsbeke, et al.
Respiratory Medicine
|
June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Page
of 6